NANETS produces a weekly publication, Weekly Net Connection. It contains information on recent NET disease research, guidelines and resources. It also highlights NET continuing medical education (CME) programming, medical society developments, member accomplishments and news from other NET organizations. Have news to share? Contact us! Net News is a benefit of membership in NANETS. Not a member? Subscribe now!

Wednesday, June 16, Mark Lewis, MD was a guest on This Pathological Life Podcast where he discussed MEN Syndromes and how "pancreatic cancer need not to be viewed as a death sentence." Listen now on Apple Podcasts and Spotify.  

"The recognition of hereditary NET syndromes can be a tip-of-the-iceberg phenomenon whereby identifying a genetic cause of neuroendocrine tumors can affect the lifelong management of the index patient and lead to the discovery of affected relatives, with the opportunity to provide genetic counseling and potentially intervene earlier in a disease arising from a germline mutation," shares Dr. Lewis.

 Risk of Cancer-Specific Death for Patients Diagnosed with Neuroendocrine Tumors: A Population-Based Analysis

NANETS members Julie Hallet, MD, MSC, FRCSC and Simron Singh, MD, MPH, FRCPC recently conducted a population-based study of patients with NETs to examine cancer and noncancer deaths after diagnosis.  

This study was published June 4 in the Official Journal of the National Comprehensive Cancer Network. Read the full analysis here.

In this study, Dr. Hallet et al used linked administrative health databases to describe the causes of death for 8607 patients with neuroendocrine neoplasms. They found that, generally, cancer-specific deaths were higher in NET patients, but some subgroups (e.g. those with nonmetastatic gastric, small intestine, colonic, and rectal NETs) were more likely to die of other causes than their NET.
Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms

NANETS member Amro Abdelrahman, MD conducted a population-based study to assess sex-based differences in prognosis of a contemporary cohort of gastroenteropancreatic-neuroendocrine neoplasm (GEP-NEN) patients.

This study was published May 5 in the NANETS affiliated medical journal Pancreas. View the full study here.
Upon joining, NANETS members receive free online access to Pancreas, a $1,678 annual value. Learn more about NANETS membership benefits on our website.


In 2021, NANETS is pleased to offer two research grants to encourage young researchers and scientific clinicians to become NET specialists. The NANETS research grant submission portal opened May 1 and will accept submissions through July 2, 11:59 PM PDT. Interested applications can access the research grant submission portal here.
NANETS Clinical Investigator Scholarship (NCIS): The NCIS is a $100,000 scholarship awarded over a two-year period that emphasizes both the professional development of the scientific clinician (whose time is primarily dedicated to patient care) and the potential of the project to directly impact NET patients. Learn more here.

NANETS Basic/Translational Science Investigator (BTSI): The BTSI is a $100,000 grant awarded over the period of two years to scientists at the end of their fellowship or in the beginning of their faculty appointments who are predominantly focused on lab-based, basic/translational research. Learn more here.

Special thanks to Ipsen Biopharmaceuticals and The Neuroendocrine Tumor Research Foundation (NETRF) for their sponsorship and support of NANETS' 2021 research grant program. Visit our website for more information and instructions on how to apply.